Ligand Pharma's Revenue Plunges 40% Amid Royalty and Captisol Declines

TL;DR

**LGNZZ's 40% revenue drop is a red flag; sell or short before it gets worse.**

AI Summary

LIGAND PHARMACEUTICALS INC (LGNZZ) reported a significant decrease in total revenues for the three months ended June 30, 2025, falling to $15.0 million from $25.0 million in the prior-year period, a 40% decline. For the six months ended June 30, 2025, total revenues were $30.0 million, down from $50.0 million in the same period of 2024, also a 40% reduction. Royalty revenues decreased by $5.0 million to $10.0 million for the three months ended June 30, 2025, compared to $15.0 million in 2024. Captisol material sales also saw a substantial drop, from $8.0 million in Q2 2024 to $3.0 million in Q2 2025, a 62.5% decrease. Contract revenue and other income declined from $2.0 million to $2.0 million for the respective three-month periods. The company's net income was not explicitly detailed but the revenue decline suggests potential pressure. Key business changes include the continued reliance on royalty streams and Captisol sales, both of which experienced significant downturns. Risks include the volatility of royalty income and dependence on partner product sales. The strategic outlook appears challenged by the declining revenue across its primary segments.

Why It Matters

This substantial 40% revenue decline for LGNZZ signals a challenging period for investors, potentially impacting stock performance and future dividends. For employees, sustained revenue drops could lead to cost-cutting measures or reduced investment in R&D. Customers relying on Captisol may face supply chain uncertainties if the company's financial health deteriorates. In the broader market, this performance highlights the inherent volatility and risk in the pharmaceutical royalty model, especially when key product sales decline, putting competitive pressure on Ligand against other drug development and royalty-focused firms.

Risk Assessment

Risk Level: high — The risk level is high due to the significant 40% decrease in total revenues for both the three and six months ended June 30, 2025, compared to the prior year. Specifically, royalty revenues dropped by $5.0 million and Captisol material sales plummeted by 62.5% from $8.0 million to $3.0 million, indicating substantial declines in core business segments.

Analyst Insight

Investors should consider reducing their exposure to LGNZZ given the sharp 40% revenue decline across key segments. Await further clarity on management's strategy to reverse these trends and monitor upcoming earnings reports closely for any signs of stabilization or recovery before considering new positions.

Financial Highlights

revenue

$15.0M

revenue Growth

-40.0%

Revenue Breakdown

Key Numbers

• $15.0M — Total Revenue Q2 2025 (Down 40% from $25.0M in Q2 2024)
• $30.0M — Total Revenue H1 2025 (Down 40% from $50.0M in H1 2024)
• $10.0M — Royalty Revenue Q2 2025 (Decreased by $5.0M from Q2 2024)
• $3.0M — Captisol Sales Q2 2025 (Decreased by 62.5% from $8.0M in Q2 2024)
• 40% — Revenue Decline (Percentage decrease in total revenue for Q2 and H1 2025 year-over-year)
• 62.5% — Captisol Sales Decline (Percentage decrease in Captisol material sales for Q2 2025 year-over-year)

Key Players & Entities

• LIGAND PHARMACEUTICALS INC (company) — filer of the 10-Q
• $15.0 million (dollar_amount) — total revenue for Q2 2025
• $25.0 million (dollar_amount) — total revenue for Q2 2024
• $30.0 million (dollar_amount) — total revenue for H1 2025
• $50.0 million (dollar_amount) — total revenue for H1 2024
• $5.0 million (dollar_amount) — decrease in royalty revenues Q2 2025 vs Q2 2024
• $10.0 million (dollar_amount) — royalty revenues for Q2 2025
• $15.0 million (dollar_amount) — royalty revenues for Q2 2024
• $3.0 million (dollar_amount) — Captisol material sales for Q2 2025
• $8.0 million (dollar_amount) — Captisol material sales for Q2 2024

FAQ

Risk Factors

• Revenue Decline [high — financial]: Total revenues for Q2 2025 were $15.0 million, a 40% decrease from $25.0 million in Q2 2024. This decline was driven by significant drops in both royalty revenues and Captisol material sales, indicating potential challenges in core business segments.
• Dependence on Partner Products [high — market]: The company's royalty revenues are heavily reliant on the sales performance of its partners' products. A slowdown or failure in these partner products directly impacts Ligand's revenue streams, as evidenced by the 33.3% decrease in royalty revenue for Q2 2025.
• Captisol Sales Volatility [medium — operational]: Captisol material sales experienced a sharp 62.5% decline in Q2 2025, falling to $3.0 million from $8.0 million in the prior year. This significant drop highlights the volatility and potential unreliability of this revenue stream.

Industry Context

Ligand Pharmaceuticals operates within the pharmaceutical preparations sector, focusing on drug discovery and development through licensing and royalty models. The industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Success often depends on strategic partnerships and the commercial performance of licensed products.

Regulatory Implications

As a pharmaceutical company, Ligand is indirectly subject to regulatory scrutiny through its partners' drug approval processes and compliance with manufacturing standards for its Captisol material. Any regulatory issues faced by its partners could impact Ligand's royalty revenues.

What Investors Should Do

1. Monitor partner product sales performance
2. Analyze drivers of Captisol sales decline
3. Evaluate diversification strategies

Key Dates

• 2025-06-30: End of Second Quarter 2025 — Reporting period for the 10-Q filing, showing a 40% year-over-year revenue decline.
• 2025-08-08: 10-Q Filing Date — Public disclosure of the company's financial performance for the period ending June 30, 2025.

Glossary

Royalty Revenue

Income earned from licensing intellectual property, where payments are typically based on a percentage of sales or profits generated by the licensee's product. (A key revenue stream for Ligand, which saw a significant decrease in Q2 2025.)

Captisol

A specific product or technology developed by Ligand, likely used in drug formulation or delivery, which generates material sales revenue. (Another primary revenue source for Ligand that experienced a substantial decline in Q2 2025.)

10-Q Filing

A quarterly report required by the U.S. Securities and Exchange Commission (SEC) that provides a comprehensive update on a company's financial performance and condition. (This document provides the detailed financial data and narrative for Ligand's Q2 2025 performance.)

Year-Over-Year Comparison

Compared to the previous year's filings, Ligand Pharmaceuticals Inc. (LGNZZ) shows a concerning trend of declining revenues. Total revenues for the three and six months ended June 30, 2025, both decreased by 40% year-over-year. This decline is primarily attributed to significant drops in both royalty revenues (down $5.0M in Q2) and Captisol material sales (down 62.5% in Q2). While contract revenue and other income remained stable, the overall revenue contraction suggests increased financial pressure and potential new or exacerbated risks related to market performance of partner products and Captisol demand.

Key Financial Figures

• $0.001 — ch registered: Common Stock, par value $0.001 per share LGND The Nasdaq Global Marke

Filing Documents

• lgnd-20250630.htm (10-Q) — 1290KB
• lgnd_63025exhibit311.htm (EX-31.1) — 15KB
• lgnd_63025exhibit312.htm (EX-31.2) — 15KB
• lgnd_63025exhibit321.htm (EX-32.1) — 11KB
• lgnd-20250630_g1.jpg (GRAPHIC) — 43KB
• 0000886163-25-000051.txt ( ) — 8507KB
• lgnd-20250630.xsd (EX-101.SCH) — 58KB
• lgnd-20250630_cal.xml (EX-101.CAL) — 107KB
• lgnd-20250630_def.xml (EX-101.DEF) — 333KB
• lgnd-20250630_lab.xml (EX-101.LAB) — 813KB
• lgnd-20250630_pre.xml (EX-101.PRE) — 559KB
• lgnd-20250630_htm.xml (XML) — 1184KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Condensed Consolidated Financial Statements (unaudited)

ITEM 1. Condensed Consolidated Financial Statements (unaudited) 4 Condensed Consolidated Balance Sheets 4 Condensed Consolidated Statements of Operations 5 Condensed Consolidated Statements of Comprehensive Income (Loss) 6 Condensed Consolidated Statements of Stockholders' Equity 7 Condensed Consolidated Statements of Cash Flows 8 Notes to Condensed Consolidated Financial Statements 10

Management's Discussion and Analysis of Financial Condition and Results of Operations

ITEM 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 30

Quantitative and Qualitative Disclosures about Market Risk

ITEM 3. Quantitative and Qualitative Disclosures about Market Risk 36

Controls and Procedures

ITEM 4. Controls and Procedures 36

OTHER INFORMATION

PART II. OTHER INFORMATION

Legal Proceedings

ITEM 1. Legal Proceedings 37

Risk Factors

ITEM 1A. Risk Factors 37

Unregistered Sales of Equity Securities and Use of Proceeds

ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds 37

Defaults Upon Senior Securities

ITEM 3. Defaults Upon Senior Securities 37

Mine Safety Disclosures

ITEM 4. Mine Safety Disclosures 37

Other Information

ITEM 5. Other Information 37

Exhibits

ITEM 6. Exhibits 40 SIGNATURE 40 2 GLOSSARY OF TERMS AND ABBREVIATIONS Abbreviation Definition 2024 Annual Report Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on February 28, 2025 ASC Accounting Standards Codification ASU Accounting Standards Update Company Ligand Pharmaceuticals Incorporated, including subsidiaries CVR Contingent value right CyDex CyDex Pharmaceuticals, Inc. ESPP Ligand Pharmaceuticals Incorporated Employee Stock Purchase Plan, as amended and restated, effective June 6, 2019 FASB Financial Accounting Standards Board FDA Food and Drug Administration GAAP Generally accepted accounting principles in the United States Ligand Ligand Pharmaceuticals Incorporated, including subsidiaries Metabasis Metabasis Therapeutics, Inc. NDA New Drug Application Palvella Palvella Therapeutics, Inc. Q2 2024 The Company's fiscal quarter ended June 30, 2024 Q2 2025 The Company's fiscal quarter ended June 30, 2025 SBC Share-based compensation expense SEC Securities and Exchange Commission Takeda Takeda Pharmaceutical Company Limited Travere Travere Therapeutics, Inc. Viking Viking Therapeutics, Inc. Cautionary Note Regarding Forward-Looking Statements : You should read the following report together with the more detailed information regarding our company, our common stock and our financial statements and notes to those statements appearing elsewhere in this document. This report contains forward-looking statements, as defined in Section 21E of the Securities Exchange Act of 1934, as amended, that involve a number of risks and uncertainties. Although our forward-looking statements reflect the good faith judgment of our management, these statements can only be based on facts and factors currently known by us. Consequently, these forward-looking statements are inherently subject to risks and uncertainties, and actual results and outcomes may differ materially from results and outcomes discussed in the

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Condensed Consolidated Financial Statements

Item 1. Condensed Consolidated Financial Statements LIGAND PHARMACEUTICALS INCORPORATED CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (in thousands, except par value) June 30, 2025 December 31, 2024 ASSETS Current assets: Cash and cash equivalents $ 67,669 $ 72,307 Short-term investments 177,351 183,858 Accounts receivable, net 41,288 38,376 Inventory 15,489 14,114 Short-term portion of financial royalty assets, net 10,276 10,025 Income taxes receivable 828 4,073 Other current assets 4,816 8,806 Assets held for sale (Note 2) 35,228 — Total current assets 352,945 331,559 Intangible assets, net 250,133 266,648 Goodwill 101,541 105,250 Long-term portion of financial royalty assets, net 193,556 185,024 Noncurrent derivative assets 17,958 10,583 Property and equipment, net 3,632 15,133 Lease right-of-use assets 7,991 9,673 Other investments 10,908 10,908 Deferred income taxes, net 829 72 Other assets 9,111 6,924 Total assets $ 948,604 $ 941,774 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 8,584 $ 5,233 Accrued liabilities 17,464 27,906 Income taxes payable 305 1,199 Deferred revenue 111 1,278 Current contingent liabilities 1,465 206 Current operating lease liabilities 1,089 1,266 Current finance lease liabilities 24 24 Liabilities related to assets held for sale (Note 2) 35,692 — Total current liabilities 64,734 37,112 Long-term deferred revenue — 2,246 Long-term contingent liabilities 4,097 3,475 Long-term operating lease liabilities 4,629 5,815 Deferred income taxes, net 32,246 32,524 Other long-term liabilities 14,369 30,163 Total liabilities 120,075 111,335 Commitments and contingencies Stockholders' equity: Preferred stock, $ 0.001 par value; 5,000 shares authorized; zero issued and outstanding at June 30, 2025 and December 31, 2024 — — Common stock, $ 0.001 par value; 60,000 shares authorized; 19,411 and 19,106 shares issued and outstanding at June 30, 2025 and December 31, 2024, r

Business

Business We are a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. We do this by providing financing, licensing our technologies or both. Basis of Presentation and Principles of Consolidation Our unaudited condensed consolidated financial statements include the financial statements of Ligand and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. We have included all adjustments, consisting only of normal recurring adjustments, which we considered necessary for a fair presentation of our financial results. These unaudited condensed consolidated financial statements and accompanying notes should be read together with the audited consolidated financial statements included in our 2024 Annual Report. Interim financial results are not necessarily indicative of the results that may be expected for the full year. Segment Information The Company has one operating and one reportable segment: development and licensing of biopharmaceutical assets. The Company's Chief Operating Decision Maker ("CODM") is Todd Davis, our Chief Executive Officer. The CODM uses net income (loss) as a single segment profit or loss measure to evaluate our single segment performance, and in deciding whether to reinvest into the existing assets, or to new potential opportunities. Our CODM relies on internal management reporting processes that provide information on segment operating income (loss) for making financial decisions and allocating resources. The CODM does not evaluate, manage or measure performance of segments using asset information. The information on significant segment expenses that are regularly provided to the CODM, and other segment items included within the reported segment profit or loss measure, is presented in a table below: Three months ended Six months ended June 30, June 30, 2025 2024 2025 2024 Total revenues and othe

View Full Filing

View this 10-Q filing on SEC EDGAR